October 17, 2017

EthOss® continues European expansion

EthOss® Regeneration Ltd has further increased its international profile in the global dental market after signing a series of new distribution and partnership deals across Eastern Europe.

Following the launch of EthOss® in 2015, the company has achieved rapid growth in the UK and internationally. The latest move in to Eastern Europe has seen deals signed with partners in Poland, Czech Republic, Slovakia, Bulgaria, Croatia and Romania, with trials of EthOss® products also ongoing in Ukraine and Russia.

The latest expansion of EthOss® in to Eastern Europe follows the news earlier in the year in which the company announced that it had signed a number of deals with partners across Western Europe.

EthOss® is an innovative synthetic bone graft solution for dental implants. The unique composition of EthOss®, which has a built-in cell-occlusive barrier, removing the need for a separate collagen membrane, provides a highly stable graft and typically produces 50 per cent new bone after 12 weeks.

EthOss® is a bi-phasic synthetic material made from a mixture of beta tri calcium phosphate and calcium sulfate and is completely free from animal or human content.  The built-in membrane function prevents soft tissue ingress and helps to dramatically speed up healing times, by allowing the periosteum (and the related blood supply) direct contact with the graft site.  This means surgical procedures can be completed much more quickly and reliably, benefitting both patient and dentist.

All of the new international relationships have come as a result of a successful exhibition at the IDS trade fair in Cologne, Germany – the biggest dental exhibition in the world – at which EthOss® exhibited on the UK Pavilion with assistance and funding from the government’s Department for International Trade. The company’s Clinical Director, Dr Peter Fairbairn, also hosts regular talks and forums with distributors and dental practitioners across the Eastern Europe region to discuss the clinical benefits of EthOss®.

Dr Paul Harrison, Managing Director of EthOss® Regeneration, said: “Despite our relative youth as a company, we are enjoying extraordinary levels of growth, particularly through international markets.

“We have now established market share and product awareness for EthOss® right across Europe and in a very short amount of time. Europe is a natural first choice for us as medical device regulation is harmonised across the EU, meaning we can quickly launch without having to seek separate approvals.

“Eastern Europe is a particularly important market for EthOss® as it is well established in the field of dental grafting. We have built excellent relationships with both dental practitioners and distributors across the region. The feedback – clinically and anecdotally – has been universally positive.”